ArticleCurrent pharmaceutical design2025
Mechanisms of a Patented Chinese Herbal Medicine for Treating Hypothyroidism in
Article in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundQu's formula 6 (QUF6), a patented Chinese herbal medicine, is used to treat hypothyroidism in the context of in vitro fertilization-embryo transfer (IVF-ET). This research aims to identify the potential bioactive components and elucidate the underlying molecular mechanisms by which QUF6 cures hypothyroidism during IVF-ET. MATERIALS AND
methodsTo find the active components of QUF6, the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and relevant literature were searched. GeneCards and other resources were used to find the targets associated with hypothyroidism and IVF-ET. Using Cytoscape software, the network of interactions was created between the targets and components, the proteinprotein interaction (PPI) network was built, and significant targets were verified. Afterward, Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed on crucial targets. Finally, molecular docking and dynamic modeling were carried out to analyze the essential components and core targets of QUF6.
resultsBy creating an interaction network, it was discovered that 92 active components in QUF6 can operate on 25 disease-related targets, with quercetin and other components playing important pharmacodynamic roles. Tumor necrosis factor (TNF), interleukin-6 (IL-6), interleukin-1B (IL-1B), apoptosis regulator Bcl-2 (BCL2), prostaglandin G/H synthase 2 (PTGS2), cellular tumor antigen p53 (TP53), and epidermal growth factor (EGF) were the main targets for the therapy of hypothyroidism. The KEGG pathway enrichment study identified 91 signaling pathways, whereas the GO enrichment analysis identified 1608 entries. Through molecular docking and MD simulations, stable binding was identified between the top five active constituents and the top seven potential targets.
conclusionQuercetin, beta-sitosterol, kaempferol, 7-ketocholesterol, and rehmapicrogenin were determined to be the active ingredients in QUF6. The potential mechanism of action for QUF6 may involve modulation of TNF, IL6, IL1B, BCL2, PTSG2, TP53, and EGF to regulate oxidative stress levels, inflammation responses, and apoptosis processes associated with hypothyroidism during IVF-ET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.